Key result
Thioridazine was not associated with an increased risk of cardiac arrest or ventricular arrhythmia compared with haloperidol (RR 0.9; 95% CI 0.7-1.2), except at doses ≥600 mg.
Why the study?
Do antipsychotic drugs increase the risk of cardiac arrest or ventricular arrhythmia in patients with schizophrenia compared to non-schizophrenic controls?
Population
Outpatients with schizophrenia treated with clozapine, haloperidol, risperidone, or thioridazine, and…
Comparison
Antipsychotic drugs vs Non-schizophrenic controls and active comparator
Design
Cohort
Authors
Loading...
Supports similar arrhythmia risk for standard-dose thioridazine versus haloperidol; leaves open broader antipsychotic effects versus non-schizophrenic controls.
Cohort
Yes
Do antipsychotic drugs increase the risk of cardiac arrest or ventricular arrhythmia in patients with schizophrenia compared to non-schizophrenic controls?
Relative Risk: 0.9 (95% CI 0.7–1.2)
Patients with treated schizophrenia have a higher risk of cardiac arrest and ventricular arrhythmia compared to controls, with high-dose thioridazine showing a dose-dependent increased risk compared to haloperidol.
Sean Hennessy (2002) conducted a cohort in schizophrenia. thioridazine vs. haloperidol was evaluated on Diagnosis of cardiac arrest or ventricular arrhythmia (RR 0.9, 95% CI 0.7 to 1.2). Thioridazine was not associated with an increased risk of cardiac arrest or ventricular arrhythmia compared with haloperidol (RR 0.9; 95% CI 0.7-1.2), except at doses ≥600 mg.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: